Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1059613 | 0.72 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL610404 | 0.72 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL15885534 | 0.71 | TP53 (0.36) | FGFR1 | |
| SCHEMBL1855848 | 0.71 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL30507890 | 0.69 | DRD2 (0.33) | — | |
| SCHEMBL19229781 | 0.68 | MEN1 (0.40) | ALDH1A1MEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL15034179 | 0.68 | CHRM2 (0.37) | ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL19229784 | 0.67 | RAB9A (0.42) | ALDH1A1MEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL14578716 | 0.66 | TP53 (0.32) | — | |
| SCHEMBL18948371 | 0.66 | CHRM2 (0.35) | ALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105051031-B | Process for the preparation of 1- ([1,3] dioxolan-4-ylmethyl) -1H-pyrazol-3-amine | 华医药 | 2017-10-10 | — | — | CN | disclosed |
| US-9388168-B2 | Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine | HUA MEDICINE (KY) | 2016-07-12 | — | — | US | disclosed |
| CN-105051031-A | Process for the preparation of 1- ([1,3] dioxolan-4-ylmethyl) -1H-pyrazol-3-amine | HUA MEDICINE | 2015-11-11 | — | — | CN | disclosed |
| CN-105051031-A | Process for the preparation of 1- ([1,3] dioxolan-4-ylmethyl) -1H-pyrazol-3-amine | HUA MEDICINE | 2015-11-11 | — | — | CN | disclosed |
| US-20150315176-A1 | Process for the Preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2015-11-05 | — | — | US | disclosed |
| EP-2938609-A1 | PROCESS FOR THE PREPARATION OF 1-([1,3]DIOXOLAN-4-YLMETHYL)-1H-PYRAZOL-3-YLAMINE | Hua Medicine (CN) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014102164-A1 | PROCESS FOR THE PREPARATION OF 1-([1,3]DIOXOLAN-4-YLMETHYL)-1H-PYRAZOL-3-YLAMINE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315176-A1 | Process for the Preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine | ACTN1, ACTB, ROCK1 | ALDH1A1 569/4885MEN1 669/4885KMT2A 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.